Why Did Enfusion Plunge 40.37%?
Generated by AI AgentAinvest Movers Radar
Thursday, Apr 17, 2025 6:47 am ET1min read
ENFN--
On April 17, 2025, Enfusion's stock experienced a significant drop of 40.37% in pre-market trading, raising concerns among investors and analysts alike.
Piper Sandler recently adjusted their price target for EnfusionENFN--, increasing it from $10.00 to $11.50 and maintaining a "neutral" rating. This adjustment reflects the firm's assessment of the company's current market position and future prospects.
Analysts have set an average price target of $12.25 for Enfusion, which is 13.27% higher than the current price. The consensus rating among analysts is "Buy," indicating a generally positive outlook on the stock's potential for growth.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet